Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TTT-3002

Known as: FLT3 Tyrosine Kinase Inhibitor TTT-3002 
An orally bioavailable indolocarbazole derivative and inhibitor of constitutively active mutant forms of FMS-like tyrosine kinase 3 (FLT3) with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
More than 35% of acute myeloid leukemia (AML) patients harbor a constitutively activating mutation in FMS-like tyrosine kinase-3… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
There have been a number of clinical trials testing the efficacy of FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors… Expand
Is this relevant?
Review
2014
Review
2014
There have been a number of clinical trials testing the efficacy of FLT3 tyrosine kinase inhibitors (TKIs) in acute myeloid… Expand
Is this relevant?
2014
2014
There have been a number of clinical trials testing the efficacy of FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
http://bloodjournal.hematologylibrary.org/content/123/10/1525.full.html Updated information and services can be found at: (1176… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent known cause of late-onset Parkinson's disease (PD). To… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Over 35% of acute myeloid leukemia (AML) patients harbor a constitutively activating mutation in FLT3 , either internal tandem… Expand
Is this relevant?
2012
2012
Abstract 866 Acute myeloid leukemia (AML) is a hematologic malignancy characterized by increased myeloproliferation and a block… Expand
Is this relevant?
2012
2012
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Acute myeloid leukemia (AML) is a hematologic… Expand
Is this relevant?